Compounded Semaglutide

GLP-1 Weight Loss

Choose a treatment option

Subcutaneous Injection

Precise, reliable dosing; ideal for peptides that can't survive digestion

From $55/mo

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. While originally developed for the management of type 2 diabetes, it is widely utilized for chronic weight management in adults with obesity or overweight conditions. It mimics a natural hormone in the body that targets areas of the brain that regulate appetite and food intake.

Check eligibility

Semaglutide is not FDA-approved to diagnose, treat, or cure any disease other than those specifically indicated on your prescription.

Why it works

Key benefits

Weight Reduction: Support for significant and sustained weight loss when combined with lifestyle changes.

Cardiovascular Support: Reduction in the risk of major adverse cardiovascular events in certain populations.

Glycemic Control: Improvement in blood sugar levels and HbA1c.

Metabolic Health: Potential improvements in blood pressure and cholesterol levels.

Based on clinical trials

Mechanism

How it works

Semaglutide acts as a "GLP-1 mimetic," influencing the body’s metabolic and appetite-control systems in three primary ways: Appetite Regulation: It sends signals to the brain to increase feelings of fullness (satiety) and decrease hunger. Gastric Emptying: It slows the rate at which the stomach empties, helping you feel satisfied longer after a meal. Insulin Modulation: It stimulates the pancreas to release insulin when blood sugar is high and reduces the liver's production of glucagon (a hormone that raises blood sugar).

Frequently asked questions

FAQs

Appetite suppression and early satiety may be noticed within the first 1–2 weeks. Significant weight loss is typically a gradual process, with the most notable results occurring after reaching the effective maintenance dose (usually by month 3 or 4). Success is highly dependent on consistent use and concurrent dietary and activity modifications.

The most common side effects are gastrointestinal and typically decrease as the body adjusts: Nausea, vomiting, or diarrhea. Constipation or abdominal pain. Heartburn or sulfur-smelling burps. Rare but serious: Pancreatitis, gallbladder problems, or kidney issues.

Before you begin

Informed Consent & Safety

Note: Report any severe abdominal pain that radiates to the back or persistent vomiting to your provider immediately.

Research & Studies

Evidence at a Glance

1.
Wilding, J. P., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
2.
Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. (Foundational GLP-1 research).
3.
Kushner, R. F., et al. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Clinical Program. Obesity.
4.
Dahl, D., et al. (2022). Effects of Semaglutide on Cardiovascular Outcomes in People with Overweight or Obesity. Circulation.

Interested in Compounded Semaglutide?

Take a short assessment and a licensed provider will review if this treatment is right for you.

Check eligibility

Clinical Guidance Disclaimer

The information provided in this document is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. It should never replace sound clinical judgment or personalized advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read in these materials.

Liability & Indemnification

By utilizing this information, the user acknowledges and agrees that REBL and its affiliates, providers, and staff are not liable for any direct, indirect, or consequential damages resulting from the use or misuse of the information provided herein. Any reliance on the materials contained in this document is solely at the user's own risk.

Proprietary Rights & Use Restrictions

This document and its contents are the proprietary property of REBL. Unauthorized use, duplication, reproduction, or distribution of these materials—in whole or in part—without express written consent is strictly prohibited.